| Troxerutin Basic information |
| Product Name: | Troxerutin |
| Synonyms: | 3μ,4μ,7-Tris[O-(2-hydroxyethyl)]rutin, Troxerutin;Troxerutin,Trihydroxyethylrutin;3',4',7-Tris(hydroxyethyl)rutin;3,5-Dihydroxy-3',4',7-tris(2-hydroxyethoxy)flavone 3-rutinoside;Factor-P-zyma;2-[3,4-BIS(2-HYDROXYETHOXY)PHENYL]-3-[[6-O-(6-O-DEOXY-A-L-MANNOPYRANOSYL)-BETA-D-GLUCOPYRANOSYL]OXY]-5-HYDROXY-7-(2-HYDROXYETHOXY)-4H-1-BENZOPYRAN-4-ONE;Trihydroxylrutin;Trihydroxyethylrutoside |
| CAS: | 7085-55-4 |
| MF: | C33H42O19 |
| MW: | 742.68 |
| EINECS: | 230-389-4 |
| Product Categories: | Intermediates & Fine Chemicals;Pharmaceuticals;Miscellaneous Natural Products;Natural Plant Extract;Inhibitors;TROXEPURE;Aromatics;Heterocycles;Oligosaccharides;Plant extracts;Herb extract;POSORUTIN |
| Mol File: | 7085-55-4.mol |
 |
|
| Troxerutin Chemical Properties |
| Melting point | 181°C |
| Boiling point | 1058.4±65.0 °C(Predicted) |
| density | 1.65±0.1 g/cm3(Predicted) |
| storage temp. | Refrigerator |
| solubility | Freely soluble in water, slightly soluble in ethanol (96 per cent) and practically insoluble in methylene chloride. |
| pka | 5.92±0.40(Predicted) |
| form | neat |
| Merck | 14,9789 |
| BRN | 4778232 |
| InChIKey | KMPBUGGPUQOWMJ-NXPSPVSKSA-N |
| CAS DataBase Reference | 7085-55-4(CAS DataBase Reference) |
| Safety Information |
| Safety Statements | 22-24/25 |
| WGK Germany | 3 |
| RTECS | LK8331500 |
| MSDS Information |
| Provider | Language |
|---|---|
| 3',4',7-Tris[O-(2-hydroxyethyl)]rutin | English |
| Troxerutin Usage And Synthesis |
| Chemical Properties | Yellow Powder |
| Originator | Venoruton,Novartis Co |
| Uses | Used in the treatment of venous disorders |
| Uses | vasoprotectant |
| Uses | Troxerutin, a derivative of the naturally occurring bioflavonoid rutin, is thought to inhibit red cell and platelet aggregation, improve erythrocyte deformability, and improve plasma viscosity retinal microcirculation. A double-blind randomized clinical trial compared troxerutin with placebo in 27 patients with CRVO. The limitations of the study included a small number of patients and short follow-up time. |
| Manufacturing Process | In a nitrogen atmosphere 120 g of caustic soda (3 moles) in solution are added to 610 g of rutin (1 mol) suspended in 2 litres of water, the mixture being vigorously agitated by a mechanical stirrer, 241.5 g of ethylene chlorohydrin being then introduced at 55°C for 10 min. When all the chlorohydrin has been thus added the temperature is progressively raised to 75°C and maintained at this level for 2 hours. After cooling, in a nitrogen atmosphere, the pH value adjusted to 5 by the addition of dilute hydrochloric acid. The solution is kept in an ice box for 24 hours and then filtered to remove any impurities. At reduced pressure the solution is evaporated until dry, the residue taken up in 3 litres of boning methanol which dissolves the tri-(β-hydroxyethyl)rutin formed and leaves the sparingly soluble sodium chloride behind. The tri-(β-hydroxyethyl)rutin is recovered from its methanolic solution either by evaporation and refrigeration, or by evaporation precipitation with absolute ethanol. In either case tri-(β-hydroxyethyl)rutin obtained is in the form of small very hygroscopic crystals which contain alcohol of crystallization.These crystals are quickly shaken washed in a little cold absolute ethanol and then dried in vacuum at 100°C. 680 g of anhydrous tri-(β-hydroxyethyl)rutin are thus obtained in the form of a yellow powder which melts at 156°C.GB Patent No. 833,174; April 21, 1960; Assigned to Zyma S.A., a Swiss Corporation, of Route Etraz, Nyon Canton of Vaud, Switzerland |
| Therapeutic Function | Topical venotonic |
| Troxerutin Preparation Products And Raw materials |
| Raw materials | 2-Chloroethanol-->Sodium hydroxide-->Rutin |